Lai Ching Lau
Singapore General Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lai Ching Lau.
Archives of Pathology & Laboratory Medicine | 2003
Siok Bian Ng; Qasim Ahmed; Sim Leng Tien; Christina Rudduck Sivaswaren; Lai Ching Lau
Synovial sarcoma (SS) is an uncommon soft tissue tumor that occurs primarily in the extremities of young adults, especially in the periarticular region. In this report, we describe the rare occurrence of primary SS of the pleura in a 15-year-old boy. Histologically, the tumor demonstrated monophasic morphologic findings and showed positive staining with vimentin and Bcl-2 and focally for cytokeratin CK7. Fluorescent in situ hybridization identified t(X;18) translocation. The patient developed recurrences 20 months following resection of the tumor. The literature on this uncommon entity is reviewed, and its histogenesis, differential diagnoses, and cytologic features are also discussed.
American Journal of Hematology | 2010
Daryl Tan; Gerrard Teoh; Lai Ching Lau; Alvin S. T. Lim; Tse‐Hui Lim; K.C. Yap; P. Premalatha; Zhentang Lao; Nelson Wee; Christine Choo; H.C. Wee; S. Su; Yuh Shan Lee; L. H. Lee; William L. Hwang; Y.T. Goh
Multiple myeloma is clinically heterogeneous and risk stratification is vital for prognostication and informing treatment decisions. As bortezomib is able to overcome several high‐risk features of myeloma, the validity of conventional risk‐stratification and prognostication systems needs to be reevaluated. We study the survival data of 261 previously untreated myeloma patients managed at our institution, where bortezomib became available from 2004 for the treatment of relapse disease. Patient and disease characteristics, and survival data were evaluated overall, and with respect to bortezomib exposure. Overall, the international staging system (ISS), metaphase karyotyping and interphase fluorescence in situ hybridization (FISH) were discerning of survival outcomes, where the median for the entire cohort was 5.2 years. However, when stratified by bortezomib exposure, only metaphase karyotyping was still discriminating of long‐term prognosis. The presence of an abnormal nonhyperdiploid karyotype overrides all other clinical and laboratory parameters in predicting for a worse outcome on multivariate analysis (median survival 2.6 years, P = 0.001), suggesting that bortezomib used at relapse is better able to overcome adverse risk related to high tumor burden (as measured by the ISS) than adverse cytogenetics on conventional karyotyping. Metaphase karyotyping provides additional prognostic information on tumor kinetics where the presence of a normal diploid karyotype in the absence of any high‐risk FISH markers correlated with superior survival and could act as a surrogate for lower plasma cell proliferation. Am. J. Hematol., 2010.
Cancer Genetics and Cytogenetics | 2008
Lai Ching Lau; Ping Lim; Yik Chen Lim; Li Min Teng; Tse Hui Lim; Lay Cheng Lim; Soo Yong Tan; Soon Tiong Lim; Warren G. Sanger; Sim Leng Tien
Trisomy 12, t(14;18)(q32;q21), and t(8;14)(q24.1;q11.2) were found in a 59-year-old man with B-cell chronic lymphocytic leukemia (CLL). While trisomy 12 is one of the most common cytogenetic abnormalities in chronic lymphocytic leukemia, the t(14;18) rearrangement has a strong association with follicular lymphoma and the t(8;14) is associated with T-cell neoplasia. Occurrence of these three abnormalities in CLL are rare, and the significance of this finding is unclear. Further studies of similar cases may shed additional insight into this finding.
Cancer Genetics and Cytogenetics | 2000
Puay Hoon Tan; Weng-Onn Lui; Patricia Ong; Lai Ching Lau; Miriam Tao; Yap-Yee Chong
Tumor cytogenetic analysis from 27 patients with breast cancer diagnosed at the Singapore General Hospital revealed complex karyotypic aberrations in 12 cases. The study group comprised 25 women and 2 men, ranging in age from 33 to 78 years (median 52 years). Ethnic distribution consisted of 22 Chinese, 3 Malaysian, and 2 Indian patients. Pathologic assessment disclosed 24 invasive ductal, 2 invasive mucinous, and 1 mixed invasive mucinous and ductal carcinomas. Histologic grading showed 3 grade 1, 10 grade 2, and 12 grade 3 tumors; 2 cancers were not graded, because they had been subjected to prior chemotherapy. Tumor sizes ranged from 1.5 to 10 cm (median 3 cm). Eleven cases were axillary node negative, whereas the remaining 16 node-positive cancers affected as many as 3 nodes in 8 cases and 4 or more nodes in another 8. Twenty cases demonstrated estrogen-receptor positivity, and 8 cases progesterone-receptor positivity. The spectrum of cytogenetic abnormalities involved chromosomes 1, 3, 6, 7, 8, 11, 16, and 17 and ranged from gains and deletions of both long and short arms, trisomy, monosomy, and other rearrangements. There was a trend toward the presence of karyotypic abnormalities in tumors of higher grade.
Chinese Medical Journal | 2013
Alvin Soon Tiong Lim; Tse Hui Lim; Karen Hsu Shien See; Yit Jun Ng; Yu Min Tan; Natasha Swee Lian Choo; Sherry Xin Er Lim; Yenny Yee; Lai Ching Lau; Sim Leng Tien; Kumar Sathish; Daryl Tan
Archive | 2009
Siok Bian Ng; Qasim Ahmed; Sim Leng Tien; Christina Rudduck Sivaswaren; Lai Ching Lau
Annals Academy of Medicine Singapore | 2010
Alvin S. T. Lim; Ting Jie Chen; Tse Hui Lim; Mary Tan; Lai Ching Lau; Ping Lim; Geok Yee Lee; Li Eng Loo; Fiona Pui San Liaw; Charles Chuah; Yeow Tee Goh; Sim Leng Tien
International Journal of Hematology | 2014
Fiona Pui San Liaw; Lai Ching Lau; Alvin Soon Tiong Lim; Tse Hui Lim; Geok Yee Lee; Sim Leng Tien
Indian Journal of Hematology and Blood Transfusion | 2014
Alvin S. T. Lim; Sathish Krishnan; Tse Hui Lim; Karen See; Yit Jun Ng; Yu Min Tan; Natasha Choo; Lai Ching Lau; Sim Leng Tien; Jun Ma; Daryl Tan
Cancer Genetics and Cytogenetics | 2014
Chuanfei Chen; Alvin Soon Tiong Lim; Tse Hui Lim; Lai Ching Lau; Li Min Teng; Sim Leng Tien